Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
– EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United Kingdom, and Australia – – European CTA approval to initiate the EMBRACE study in Ireland, Poland, and Greece has been
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
– EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will commence imminently – – PARADIGM TM comprises two 12-week randomized, double-blind, placebo-controlled
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
– Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – TORONTO–(BUSINESS WIRE)– Cybin Inc.
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
– Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients 1 – – Strengthened
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
– Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder (“MDD”) with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) – – Partnerships with Osmind and Thermo Fisher Scientific strengthen
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce
Cybin to Participate in the 2025 Psychedelic Science Conference
– Cybin CEO Doug Drysdale to participate in a panel discussion titled “The Home Stretch: Pivotal Trials and Preparing for Launch” on June 19, 2025 – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
– Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine (“DMT”) and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 – – Cybin’s growing intellectual property portfolio comprises more than 90 granted patents
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce